Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alpha Cognition Inc (OP: ACOGF ) 0.3894 -0.0069 (-1.74%) Streaming Delayed Price Updated: 2:21 PM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 54,067 Open 0.3872 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.3963 Today's Range 0.3800 - 0.3983 52wk Range 0.2288 - 0.7398 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Alpha Cognition Announces Change of Officer October 03, 2024 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing September 24, 2024 From Alpha Cognition Inc. Via Business Wire Performance YTD -22.12% -22.12% 1 Month -8.93% -8.93% 3 Month -26.53% -26.53% 6 Month -20.37% -20.37% 1 Year +54.65% +54.65% More News Read More Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease August 19, 2024 From Alpha Cognition Inc. Via Business Wire Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth August 13, 2024 From Alpha Cognition Inc. Via Business Wire Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease July 29, 2024 From Alpha Cognition Inc. Via Business Wire Life Science Virtual Investor Forum Presentations Now Available for Online Viewing March 08, 2024 From Virtual Investor Conferences Via GlobeNewswire Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024 March 05, 2024 From Virtual Investor Conferences Via GlobeNewswire Alpha Cognition to Present at the Life Science Investor Forum March 7th March 01, 2024 From Virtual Investor Conferences Via GlobeNewswire Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease February 22, 2024 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Provides Business Update February 12, 2024 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment January 19, 2024 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering December 22, 2023 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease December 07, 2023 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering December 04, 2023 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering October 16, 2023 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering August 31, 2023 From Alpha Cognition Inc. Via Business Wire Life Science Investor Forum: Presentations Now Available for Online Viewing June 23, 2023 From Virtual Investor Conferences Via GlobeNewswire Life Science Investor Forum Agenda Announced for June 22nd June 20, 2023 From Virtual Investor Conferences Via GlobeNewswire Alpha Cognition Launches $6.5 Million Private Placement May 30, 2023 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update March 08, 2023 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Provides Private Placement Update March 06, 2023 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update November 28, 2022 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update August 25, 2022 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease August 22, 2022 From Alpha Cognition Inc. Via Business Wire Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease June 22, 2022 From Alpha Cognition Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.